We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Recipharm Subsidiary Files Infectious Disease Drug Application in European Markets
News

Recipharm Subsidiary Files Infectious Disease Drug Application in European Markets

Recipharm Subsidiary Files Infectious Disease Drug Application in European Markets
News

Recipharm Subsidiary Files Infectious Disease Drug Application in European Markets

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Recipharm Subsidiary Files Infectious Disease Drug Application in European Markets"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

RPH Pharmaceuticals AB has announced the filing of an application for an infectious disease drug product in a range of European countries.

The product has been developed through a partnership with Swedish pharmaceutical company, Astimex Pharma AB, which is set to market the product in the Nordic market.

As a "first in class generic", the product, owned by RPH Pharmaceuticals, will be licensed to third parties for distribution in markets where Astimex presently is not represented.

In addition to the filed application, Astimex and RPH Pharmaceuticals have expanded their collaboration with another manufacturing and development project in which the drug target is another first in class generic approved for use in most of the North European markets.

The collaboration represents joint investments where Recipharm builds a registration dossier, whilst Astimex takes full responsibility for sales and distribution in the Swedish market and RPH Pharmaceuticals can out-license sales and distribution rights in other markets.

Johan Åkerblom, Business Development Manager, RPH Pharmaceuticals commented: “We are delighted that the collaboration with Astimex is proving to be so successful for both our companies. Indeed, we are greatly excited by the pace at which drug products are being developed and licensing, sales and distribution arrangements are being set in place. Furthermore, the sales potential for the collaboration products looks very promising with the infectious disease target being one clear example of this.”

Advertisement